Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Executives To Watch: Alcon Japan New President, AZ International EVP

Executive Summary

Autumn has brought a flurry of personnel changes with Kyowa FujiFilm getting a new president and AZ a new executive vice president for the international region. Fosun and the medtech firm, Median Technologies, have also seen personnel movement.

You may also be interested in...



China Micron Ban Not Cause For Further Health Sector Worry?

China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.

'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China

Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.

Chinese Language Podcast: 重磅交易, 亚太药企如何度过资本寒冬, 减肥药风口

The latest China biopharma trends, including recent multimillion dollar deals by biotech firms, companies preparing for the worst as the 'capital winter' lingers, and GLP-1 agents for obesity are discussed by Brian Yang in Beijing and Dexter Yan in Shanghai in this latest Chinese-language podcast.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB001731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel